Tyra raises $148M, extends runway to H2 2028, advances three Phase 2 trials for dabogratinib

Filed May 13, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~1 min read

Key Changes

• high

  Company raised $147.9M via ATM offering (4.7M shares sold) and extended cash runway from 'through 2027' to 'into H2 2028', funding three concurrent Phase 2 trials without near-term financing pressure.

  MD&A: Liquidity and Capital Resources verify on EDGAR →
• high

  Initiated SURF303 Phase 2a/b trial for low-grade upper tract urothelial carcinoma (LG-UTUC), dosed first patient, with initial results expected in 2027. This is the third urothelial cancer indication for dabogratinib.

  MD&A: Clinical Programs verify on EDGAR →
• high

  SURF302 (intermediate-risk bladder cancer) enrolled 20+ patients across US and international sites; initial 3-month complete response data expected August 2026. BEACH301 (pediatric achondroplasia) enrolled safety sentinel cohort; 6-month height velocity data on-track for Q4 2026.

  MD&A: Clinical Programs verify on EDGAR →